Shanghai Pharmaceuticals Sets Board Meeting to Approve 2025 Results and Consider Final Dividend

Shanghai Pharmaceuticals Holding Co ( (HK:2607) ) has provided an announcement.

Shanghai Pharmaceuticals Holding Co., Ltd. has scheduled a board meeting for 30 March 2026 to review and approve the annual results for the financial year ended 31 December 2025. The board will also consider the proposal and potential declaration of a final dividend, a decision that could affect shareholder returns and signal management’s outlook on the group’s financial performance.

The meeting underscores the company’s adherence to disclosure obligations for its Hong Kong listing and sets a clear timetable for investors awaiting full-year figures. The composition of the board, including executive, non-executive, employee, and independent non-executive directors, is also reaffirmed, highlighting the company’s existing governance structure and oversight framework.

The most recent analyst rating on (HK:2607) stock is a Hold with a HK$13.00 price target. To see the full list of analyst forecasts on Shanghai Pharmaceuticals Holding Co stock, see the HK:2607 Stock Forecast page.

More about Shanghai Pharmaceuticals Holding Co

Shanghai Pharmaceuticals Holding Co., Ltd. is a major Chinese pharmaceutical group listed in Hong Kong, operating through a network of subsidiaries. The company is engaged in the manufacture, distribution, and sale of medicines and healthcare products, serving hospital, retail, and broader healthcare markets in the PRC.

Average Trading Volume: 2,196,448

Technical Sentiment Signal: Strong Sell

Current Market Cap: HK$65.59B

For a thorough assessment of 2607 stock, go to TipRanks’ Stock Analysis page.